The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies
    Sun, Chenxi
    Chen, Huixian
    Wang, Yongjing
    Zheng, Chengyun
    HEMATOLOGY, 2023, 28 (01)
  • [42] Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis
    Zeng, Siyuan
    Liu, Daju
    Yu, Yongai
    Zou, Lei
    Jin, Xianyu
    Liu, Bing
    Liu, Lifeng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [43] The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety
    Wu, Yingcheng
    Shi, Hui
    Jiang, Maorong
    Qiu, Mingyan
    Jia, Keren
    Cao, Tianyue
    Shang, Yujuan
    Shi, Lili
    Jiang, Kui
    Wu, Huiqun
    INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (12) : 2562 - 2570
  • [44] Efficacy and safety of PD-1/PD-L1 inhibitors alone or in combination in the treatment of metastatic or advanced renal cell carcinoma: a network meta-analysis
    Zhang, Dongli
    Shen, Chong
    Zhang, Weichuan
    Chen, Haibin
    Zhao, Jianjun
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [45] Safety and efficacy analysis of PD-1 inhibitors in combination with chemotherapy for advanced pancreatic cancer
    Song, Dong
    Yang, Xuejing
    Guo, Xin
    Sun, Hu
    IMMUNOTHERAPY, 2022, 14 (16) : 1307 - 1313
  • [46] Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma
    Landwehr, Laura-Sophie
    Altieri, Barbara
    Sbiera, Iuliu
    Remde, Hanna
    Kircher, Stefan
    Olabe, Julie
    Sbiera, Silviu
    Kroiss, Matthias
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (09) : 2325 - 2334
  • [47] CTLA-4 and PD-1 pathway blockade: combinations in the clinic
    Callahan, Margaret K.
    Postow, Michael A.
    Wolchok, Jedd D.
    FRONTIERS IN ONCOLOGY, 2015, 4
  • [48] Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
    Chen, Shixue
    Zhang, Zhibo
    Zheng, Xuan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Liu, Zhefeng
    Wang, Jinliang
    Qian, Yuanyu
    Cui, Pengfei
    Huang, Di
    Huang, Ziwei
    Wu, Zhaozhen
    Hu, Yi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [49] Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
    Zhu, Jue
    Yan, Lifeng
    Wang, Qiming
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [50] Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
    Elmakaty, Ibrahim
    Abdo, Ruba
    Elsabagh, Ahmed
    Elsayed, Abdelrahman
    Malki, Mohammed Imad
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
12345